Trials / No Longer Available
No Longer AvailableNCT05918913
Expanded Access Program for Revumenib
Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Syndax Pharmaceuticals · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- —
Summary
This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revumenib | Revumenib administered orally every 12 hours. |
Timeline
- First posted
- 2023-06-26
- Last updated
- 2025-09-05
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05918913. Inclusion in this directory is not an endorsement.